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Insulin receptor substrates (IRSs) are tyrosine-phos-
phorylated following stimulation with insulin, insulin-
like growth factors (IGFs), and interleukins. A key ques-
tion is whether different IRSs play different roles to
mediate insulin’s metabolic and growth-promoting ef-
fects. In a novel system of insulin receptor-deficient
hepatocytes, insulin fails to (i) stimulate glucose phos-
phorylation, (ii) enhance glycogen synthesis, (iii) sup-
press glucose production, and (iv) promote mitogenesis.
However, insulin’s ability to induce IRS-1 and gab-1
phosphorylation and binding to phosphatidylinositol
(PI) 3-kinase is unaffected, by virtue of the compensa-
tory actions of IGF-1 receptors. In contrast, phosphoryl-
ation of IRS-2 and generation of IRS-2/PI 3-kinase com-
plexes are markedly reduced. Thus, absence of insulin
receptors selectively reduces IRS-2, but not IRS-1 phos-
phorylation, and the impairment of IRS-2 activation is
associated with lack of insulin effects. To address
whether phosphorylation of additional IRSs is also af-
fected, we analyzed phosphotyrosine-containing pro-
teins in PI 3-kinase immunoprecipitates from insulin-
treated cells. However, these experiments indicate that
IRS-1 and IRS-2 are the main PI 3-kinase-bound proteins
in hepatocytes. These data identify IRS-2 as the main
effector of both the metabolic and growth-promoting
actions of insulin through PI 3-kinase in hepatocytes,
and IRS-1 as the main substrate mediating the mito-
genic actions of IGF-1 receptors.
Insulin, IGF-1,1 and IGF-2, acting through insulin and IGF-1
receptors, promote a wide range of metabolic and growth-pro-
moting functions in typical insulin target cells, such as liver,
muscle, and fat, and to a lesser extent in other tissues. The
mechanism by which insulin regulates energy metabolism and
promotes cell growth has been extensively studied. In recent
years, a consensus has emerged that phosphorylation of IRS
molecules by the insulin receptor kinase is important for insu-
lin action (1). IRS molecules engage in the formation of signal-
ing complexes with numerous adapter molecules and enzymes
via their pY-X-X-M motifs (2–6). Thus, the IRS signaling sys-
tem provides an elegant explanation for the diversity of insulin
signaling (7). Nevertheless, the role of different IRSs in insulin
signaling, as well as the role of the numerous additional sub-
strates of the insulin receptor kinase that are distinct from IRS
has remained elusive.
Progress in this area has been hampered by the lack of
suitable in vitro systems in which phosphorylation of individ-
ual molecules can be correlated with specific biologic functions.
In fact, insulin-responsive cell lines such as 3T3-L1 adipocytes
or L6 myoblasts possess an endogenous complement of signal-
ing molecules, so that the effects of individual components can
be addressed only by way of overexpression or inhibition ex-
periments. It is significant that much progress in our under-
standing of the IRS system has derived from studies of the
myeloid cell line 32D, which carries a functional knock-out of
these molecules (8–10). However, 32D cells may not be repre-
sentative of classic target tissues of insulin action.
Targeted mutagenesis of genes of the insulin and IGF sig-
naling system in mice has provided clues as to the functional
differences among related molecules (11, 12). We and others,
for example, have shown that insulin receptors are indeed the
master switch of the insulin signaling pathway (13, 14), and
that IGF-1 receptors contribute little to metabolic regulation
(15–17). Likewise, the phenotype of mice with a genetic abla-
tion of IRS-1 has suggested that IRS-1 plays a more important
role in mediating growth than metabolic responses (18, 19).
Interestingly, however, combined heterozygosity for an insulin
receptor and an IRS-1 null allele triggers synergistic interac-
tions to impair insulin action and causes insulin-resistant di-
abetes in mice, suggesting that IRS-1 can also affect metab-
olism (20). On the other hand, mice lacking IRS-2 develop
lethal diabetic ketoacidosis as a result of combined insulin
resistance and insulin deficiency, indicating that IRS-2 plays
a crucial role in the development of mechanisms regulating fuel
homeostasis (21).
The derivation of cell lines from mice with targeted muta-
tions provides an important tool to dissect the function of these
molecules in vitro. For example, Bruning et al. (22) have been
able to show that IRS-1 and IRS-2 are not functionally inter-
changeable in mediating various growth-promoting functions
of IGF-1 in fibroblasts of IRS-1-deficient mice.
In this study, we have analyzed insulin action in permanent
cultures of hepatocytes from mice lacking insulin receptors. We
generated these cells using a well established procedure entail-
ing transformation with a temperature-sensitive mutant SV40
virus (23). We asked whether, in the absence of insulin recep-
tors, IGF-1 receptors could mediate the typical metabolic and
growth-promoting responses of insulin in hepatocytes. We re-
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port that insulin, acting through the IGF-1 receptor, mediates
IRS-1, but not IRS-2 phosphorylation, and that the failure to
phosphorylate IRS-2 correlates with the inability of these cells
to mediate insulin’s characteristic actions. Phosphorylation of
gab-1, and association of other phosphotyrosine-containing pro-
teins with the p85 subunit of PI 3-kinase, were similar in
normal and insulin receptor-deficient cells. These findings cor-
relate IRS-2 phosphorylation with both the metabolic and
growth-promoting actions of insulin, and suggest that individ-
ual IRS molecules play a more specific role in signal transduc-
tion than previously recognized.
MATERIALS AND METHODS
Derivation of Cell Lines—Livers of transgenic mice lacking insulin
receptors and normal controls were isolated between embryonic day
18.5 and postnatal day 1. The livers were digested with collagenase
(Worthington), and the resulting cells were plated in 6-cm culture
dishes. Transformation with a temperature-sensitive mutant SV40 was
performed as described previously (23). Multiple clones were isolated
and characterized. To confirm the hepatocyte lineage, albumin secre-
tion in the medium was measured using an enzyme-linked immunosor-
bent assay. The experiments described in this study were performed on
two independent clones of 2/2 cells, chosen based on high levels of
albumin secretion. 125I-insulin and 125I-IGF-1 binding were performed
according to standard techniques (13). Cells were maintained in a-min-
imal essential medium supplemented with 1 mM L-glutamine, 200 nM
dexamethasone, and 4% fetal calf serum at 33 °C. Preliminary experi-
ments were carried out at both the permissive temperature for viral
replication (33 °C) and the nonpermissive temperature (40 °C). How-
ever, none of the parameters analyzed in this study was affected by the
different temperature (24).
Immunoprecipitation and Immunoblotting—Serum-deprived cul-
tures of WT and 2/2 cells (;80% confluent) were stimulated with
insulin at various concentrations for 5 min. Cells were lysed in deter-
gent buffer containing 50 mM HEPES, pH 7.6, 150 mM NaCl, 1% Triton,
phosphatase and protease inhibitors. The lysates were immunoprecipi-
tated with the appropriate antibodies as described. In vitro phospho-
rylation of the glycoprotein fractions isolated from both cell types were
carried out as described elsewhere (13). Anti-phosphotyrosine antibod-
ies were purchased from Transduction Laboratories (Lexington, KY),
insulin receptor and IGF-1 receptor antibodies from Calbiochem, and
anti-IRS-1, anti-IRS-2, anti-Gab-1, and anti-p85 antibodies were pur-
chased from Upstate Biotechnology (Lake Placid, NY).
Glucokinase Activity—Cells were cultured in serum-free medium
overnight and incubated in the absence or presence of 100 nM insulin for
3 h. Thereafter, cells were homogenized in buffer containing 50 mM
Tris-HCl, pH 7.4, 0.3 M sucrose, 0.1 M KCl, 1 mM EDTA, and 2.5 mM
b-mercaptoethanol. Following centrifugation at 15,000 rpm for 15 min,
the post-mitochondrial supernatant was centrifuged at 180,000 3 g for
1 h to obtain the cytosolic fraction. Glucokinase activity was measured
by a spectrophotometric assay, in the presence of 45 mM Tris-HCl, pH
7.4, 110 mM KCl, 8 mM MgCl2, 0.5 mM NADP, 0.9 unit/ml glucose-6-
phosphate dehydrogenase, 100 mM glucose, and ATP (0 or 5 mM).
Glucokinase activity was calculated as the ATP-dependent rate of
NADPH formation, based on a stoichiometry of 2 mol of NADPH formed
per mol of glucose phosphorylated (25).
Hepatic Glucose Production—Cells were cultured overnight in
a-minimal essential medium supplemented with 0.25% bovine serum
albumin, and incubated in glucose- and serum-free a-minimal essential
medium supplemented with 16 mM lactate and 4 mM pyruvate in the
presence or absence of 100 nM insulin. Aliquots of medium were re-
moved at the indicated time points, and the glucose concentration was
measured with a glucose analyzer (Beckman) (26).
Glycogen Content—SV40-transformed cells were cultured in serum-
free medium as indicated above in the presence or absence of 100 nM
insulin. Thereafter, cells were homogenized in 0.6 N HClO4 and centri-
fuged, and aliquots of the supernatant were incubated with amyloglu-
cosidase in acetate buffer as described previously (27). Released glucose
was measured with a glucose analyzer.
Glycogen Synthase Activity—Cells were incubated with glucose-free
medium supplemented with dialyzed fetal calf serum for 3 h. Insulin
was added for 30 min at 37 °C. The reaction was stopped by freezing
cells in liquid nitrogen. The reaction was performed as described in
buffer containing 40 mM Tris-HCl, 25 mM NaF, 20 mM EDTA, 10 mg/ml
glycogen, 7.2 mM UDP-glucose disodium salt, with and without 6.7 mM
glucose 6-phosphate, and 0.05 mCi/60 ml [14C]UDPG for 25 min at 37 °C
(28). The incorporation of [14C]UDPG was determined in a liquid scin-
tillation counter. The ratio of glucose 6-phosphate-independent (I) gly-
cogen synthase activity was calculated as shown: % I 5 I-form/(I- 1
D-form) 3 100.
DNA Synthesis—Hepatocytes were grown to near confluence in reg-
ular medium, incubated overnight in insulin-free medium, and placed
in medium containing increasing concentrations of insulin (10210 to
1027 M) or buffer alone for 16 h. Thereafter, the medium was replaced
by the same medium supplemented with HEPES (25 mM, pH 7.4) and
[3H]thymidine (500 Ci/ml, NEN Life Science Products) for 1 h. Cells
were washed three times, solubilized, and precipitated with 20% tri-
chloroacetic acid. Radioactivity was measured in a liquid scintillation
counter (28).
Growth Curves—Hepatocytes were plated at concentrations of 5 to
50 3 104 cells/ml and allowed to attach to the plates in complete
medium. Thereafter, they were cultured for 96 h in regular medium or
1% bovine serum albumin with or without varying concentrations of
insulin, IGF-1, or IGF-2. At the end of the incubation, medium contain-
ing 2.5% neutral red (Sigma) was added for 2 h, and the absorbance was
measured at 570 nm. Cell growth was expressed as percentage of the
absorbance values. Basal values are represented by the growth of cells
incubated in 1% bovine serum albumin and maximal values by the
growth observed in cells incubated with complete medium.
RESULTS
Protein Phosphorylation in Insulin Receptor-deficient Hepa-
tocytes—Initially, we analyzed 125I-insulin binding to cells de-
rived from insulin receptor-deficient mice (hereafter referred to
as 2/2 cells). Binding competition curves (Fig. 1a) and Scat-
chard analysis (Fig. 1b) are consistent with the absence of high
affinity insulin binding sites in 2/2 cells. The residual 125I-
insulin binding (ID50 5 100 nM) detected in 2/2 cells can be
attributed to the presence of IGF-1 receptors, as we have pre-
viously shown (17). Indeed, the linear Scatchard plot of 2/2
cells is typical of binding to IGF-1 receptors (Fig. 1b). From the
intercept of the slope on the horizontal axis of the Scatchard
plot, we estimate that WT cells express ;105 insulin receptors/
cell. Previously, we have shown that the levels of expression of
IGF-1 receptors are similar in WT and 2/2 cells (;105 IGF-1
receptors/cell).
We next examined insulin-induced receptor phosphorylation.
Insulin stimulated tyrosine phosphorylation of its receptor in
WT cells, but not in 2/2 cells (Fig. 2a). On the contrary,
phosphorylation of IGF-1 receptors was similar in both cell
FIG. 1. 125I-Insulin binding competi-
tion curves for WT and 2/2 cells. a,
binding competition curves. Monolayers
were incubated with tracer amounts of 125I-
insulin (20,000 cpm/well) in the presence of
increasing amounts of unlabeled hormone.
Percent binding in WT cells is ;10%, and
in 2/2 cells ;1%. b, Scatchard analysis of
binding data. The data presented in a were
extrapolated according to Scatchard. A typ-
ical curvilinear plot is observed in WT cells,
whereas a linear plot consistent with bind-
ing of insulin to IGF-1 receptors is seen in
2/2 cells.
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types, as we have demonstrated in a previous publication (17).
To compare the ability of insulin to stimulate tyrosine phos-
phorylation of the IGF-1 receptor vis à vis the insulin receptor,
we isolated the glycoprotein fraction from Triton X-100 extracts
of WT and 2/2 cells and subjected it to in vitro phosphorylation
with g-[32P]ATP in the presence of 100 nM insulin, followed by
immunoprecipitation with anti-phosphotyrosine antibodies.
The total amount of phosphotyrosine recovered by immunopre-
cipitation in WT cells extracts was twice the amount recovered
in 2/2 cells (Fig. 2b), consistent with the fact that the total
number of insulin plus IGF-1 receptors in WT cells is double
that of 2/2 cells. The conclusion of this experiment is that
insulin at high doses is equipotent in stimulating phosphate
incorporation into insulin and IGF-1 receptors.
IRS-1 and -2 Phosphorylation and PI 3-Kinase Co-precipita-
tion—Next, we investigated the ability of insulin to activate
intracellular signaling pathways in both cell types. Insulin
stimulated tyrosine phosphorylation of IRS-1 in WT and 2/2
cells to a similar extent. In contrast, tyrosine phosphorylation
of IRS-2 was severely blunted in 2/2 cells compared with WT
cells (Fig. 3). Upon tyrosine phosphorylation, IRS molecules
bind the regulatory (p85) subunit of PI 3-kinase, leading to
increased PI 3-kinase activity. Insulin treatment led to a 3.4-
fold increase in the amount of p85 co-precipitated with IRS-1 in
WT cells, and to a 5.3-fold increase in 2/2 cells (Fig. 4b). In
contrast, the amount of p85 detected in anti-IRS-2 immunopre-
cipitates was increased 3.3-fold in WT cells, and 1.3-fold in 2/2
cells (Fig. 4c). Thus, insulin can fully activate IRS-1 through
IGF-1 receptors, whereas activation of IRS-2 is substantially
reduced. The decreased co-precipitation of p85 with IRS-2 sug-
gests that IRS-2-associated PI 3-kinase activity is reduced in
2/2 cells. In fact, it has been shown that activation of PI
3-kinase by insulin requires binding of tyrosine phosphorylated
IRSs to the SH2 domains of p85 (29–31). Thus, this experiment
provides insight into activation of PI 3-kinase in response to
insulin.
Investigation of Additional Insulin Receptor Substrates That
Associate with p85—We then addressed whether activation of
other molecules important for insulin action is also blunted in
2/2 cells. Gab-1 is a member of the IRS family, phosphoryla-
tion of which is stimulated by both insulin and IGF-1 (6).
Tyrosine phosphorylation of gab-1 in insulin-treated WT and
2/2 cells was similar (data not shown). Two additional mem-
bers of the IRS family have been described: IRS-3 and IRS-4 (4,
5). Of these, IRS-3 is known to be expressed in liver (32), while
no information is available on liver expression of IRS-4 (5).
Since we did not have specific antibodies against these two
FIG. 3. Phosphorylation of IRS-1 and IRS-2 in response to in-
sulin. Lysates from basal and insulin-treated cells were immunopre-
cipitated with anti-IRS-1 or anti-IRS-2 antibodies and blotted with
either anti-phosphotyrosine antibody (a) or with IRS-1 and IRS-2 anti-
bodies (b). A representative experiment is shown.
FIG. 2. Insulin-induced protein phos-
phorylation. a, Insulin receptors were im-
munoprecipitated from total cellular lysates
of basal or insulin-treated cells, and tyrosine
phosphorylation was measured by immuno-
blotting with anti-phosphotyrosine antibod-
ies. The blots were subsequently stripped
and reprobed with anti-insulin receptor an-
tibody (lower panel), to normalize phospho-
tyrosine content to the amount of immuno-
precipitable insulin receptors. b, insulin-
stimulated tyrosine phosphorylation in
wheat germ extracts of WT and 2/2 cells.
Glycoproteins were purified from WT and
2/2 cells using wheat germ agglutinin affin-
ity chromatography, and subjected to in
vitro phosphorylation with g-[32P]ATP. Fol-
lowing immunoprecipitation with anti-phos-
photyrosine antibodies, the immune com-
plexes were resolved on SDS-polyacrylamide
gel electrophoresis and phosphotyrosine-
containing proteins were detected by autora-
diography. The total amount of phosphoty-
rosine incorporated into the 95-kDa b
subunit of insulin and IGF-1 receptors was
calculated by scanning densitometry of the
autoradiogram (not shown), and is 2-fold
higher in WT cells compared with 2/2 cells.
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IRSs, we asked whether we could detect them in co-immuno-
precipitation assays with anti-p85 antibodies followed by anti-
phosphotyrosine immunoblots. In both cell types, the main
p85-bound phosphoproteins following insulin treatment are
represented by two broad bands at 160–180 kDa and 125 kDa
(Fig. 4a). Detailed analysis of these patterns leads us to con-
clude that, among the major p85-associated proteins, only
IRS-2 co-immunoprecipitation is significantly impaired in 2/2
cells compared with WT cells: (i) the p160–180 band can be
almost entirely immunodepleted by sequential immunoprecipi-
tation with IRS-1 and IRS-2 antibodies (compare the intensity
of the p160 band in Fig. 4, a and d, with the intensity of the
non-insulin-stimulated band present at the top of each gel). A
residual p160 band can be detected in extracts immunode-
pleted of IRS-1 and IRS-2 (Fig. 4d). This 160-kDa protein
migrates slightly more slowly than IRS-1 and IRS-2, and does
not cross-react with either antibody on Western blots. It may
represent IRS-4, or a novel member of the IRS family. Co-
precipitation of this band is similar in both cell types. A minor
band of molecular mass of 150 kDa is also present in WT cells,
and completely absent in 2/2 cells. Co-precipitation of this
tyrosine-phosphorylated protein is modestly affected by insulin
in WT cells. (ii) Co-precipitation of the p125 band is only
slightly decreased in 2/2 cells (Fig. 4a). This band probably
contains multiple molecular species, including gab-1. As stated
above, phosphorylation of gab-1 is similar in both cell types.
(iii) Following immunodepletion of IRS-1 and IRS-2, we ob-
served a 60-kDa band, co-precipitation of which is modestly
affected by insulin in WT cells (;2-fold), but not in 2/2 cells
(Fig. 4e). It is highly likely that p60 represents IRS-3 (4, 32, 33).
In summary, even though there are multiple differences in
the patterns of tyrosine-phosphorylated proteins associated
with p85, the most abundant proteins are IRS-1 and IRS-2.
Thus, they probably account for most of the PI 3-kinase activity
elicited by insulin in these cells. Therefore, IRS-2 is the prin-
ciple PI 3-kinase-bound protein, phosphorylation of which is
significantly impaired in 2/2 cells.
Effects of Insulin on Glucose Metabolism Are Blunted in 2/2
Hepatocytes—Hepatocytes are an ideal model to study insulin
action, because insulin exerts both metabolic and growth-pro-
moting effects in these cells. We asked whether the differences
observed in the signaling pathway would be mirrored by
changes in the ability of 2/2 cells to respond to insulin in
assays of glucose metabolism. Insulin stimulated glucokinase
(Fig. 5a) and glycogen synthase activities (Fig. 5b), and sup-
pressed glucose production in WT cells (Fig. 5c, left panel). In
2/2 cells, basal rates of glucokinase activity and glycogen
synthesis, as well as glycogen content (not shown) were de-
creased compared with WT cells. Glucose production rates, on
the other hand, were about 2-fold higher (Fig. 5c, right panel) in
2/2 cells. Moreover, insulin was totally ineffective in modulat-
ing these metabolic activities in 2/2 cells, despite the activa-
tion of IGF-1 receptors. Thus, IGF-1 receptor-mediated activa-
tion of IRS-1 is not sufficient to mediate insulin’s metabolic
actions in liver.
Growth-promoting Actions of Insulin—Insulin has a potent
effect to stimulate DNA synthesis and cell growth in hepato-
cytes (34). In 2/2 cells, thymidine incorporation in response to
insulin was decreased by .80% compared with normal cells,
consistent with impaired DNA synthesis (Fig. 6a). We also
FIG. 4. Pattern of tyrosine-phospho-
rylated proteins associated with the
PI 3-kinase p85 subunit. a, cell lysates
from WT and 2/2 were immunoprecipi-
tated with p85 antibodies and blotted
with anti-phosphotyrosine antibodies.
The major bands are identified with ar-
rowheads. The p60 band is barely visible
on this blot, but could be visualized more
readily following immunodepletion of the
extracts with IRS-1 and IRS-2 antibodies,
as shown in panel e. b and c, cell extracts
were immunoprecipitated sequentially
with IRS-1 (b) and IRS-2 (c) antibodies,
and blotted with p85 antibody. d and e,
following immunodepletion of IRS-1 and
IRS-2 with the relevant antibodies, ex-
tracts from WT and 2/2 cells were immu-
noprecipitated with anti-p85 antibody
and immunoblotted with anti-phosphoty-
rosine antibody. Two different gels are
shown to better visualize the regions of
the gel corresponding to 160 kDa (d) and
60 kDa (e). f, as a control for the efficiency
of the various immunoprecipitations, ex-
tracts were immunoprecipitated and im-
munoblotted with anti-p85 antibody.
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studied the ability of WT and 2/2 cells to replicate (Fig. 6b).
Both cell types grew at similar rates in the presence of serum.
Insulin and IGF-2 were equally effective in stimulating growth
of serum-deprived WT cells and ;2-fold more potent than
IGF-1. In 2/2 cells, insulin- and IGF-2-dependent growth was
decreased by ;50% (p , 0.01), while no differences were ob-
served in IGF-1-dependent growth.
DISCUSSION
In these investigations, we have analyzed the correlation
between IRSs phosphorylation and insulin action in hepato-
cytes derived from insulin receptor-deficient mice. We provide
evidence that impaired activation of IRS-2 in these cells is
associated with failure of both metabolic and growth-promoting
actions of insulin. An important result of the present study is
that ablation of insulin receptors results in a selective loss of
IRS-2 phosphorylation, in the absence of detectable changes in
IRS-1 phosphorylation. Indirect evidence suggests that addi-
tional IRSs are minor components of the IRS signaling system
in this cell type. Thus, these data support the notion that
signaling from insulin receptors to IRS-2 is required for the
characteristic actions of insulin in liver. Since our data were
obtained in the context of a physiologic target cell of insulin
action, we believe that they add significant new information to
our understanding of the insulin signaling system.
The link between impaired phosphorylation of IRS-2 and
impaired insulin action is further demonstrated by the de-
crease in the formation of IRS-2/PI 3-kinase complexes in 2/2
cells. There is substantial evidence that PI 3-kinase is required
for many, if not all, of insulin actions (35–46). While in this
study we did not measure PI 3-kinase activity directly, it is well
established that insulin activates PI 3-kinase by causing IRSs
to bind to the SH2 domains of the p85 subunit (29–31). Thus,
there is an excellent correlation between co-precipitation of
IRSs with p85 and PI 3-kinase activity. Our analysis of the
patterns of tyrosine-phosphorylated proteins detected in p85
immunoprecipitates indicates that the main proteins bound to
p85 in hepatocytes are indeed IRS-1 and IRS-2, and therefore
account for most of PI 3-kinase activity elicited by insulin in
these cells. Furthermore, we have recently been able to show
that insulin fails to stimulate Akt activity in 2/2 cells, which is
consistent with an impairment of PI 3-kinase activity2 (47–50).
These data provide support to the notion that impairment of
IRS-2 phosphorylation in 2/2 cells is one of the mechanisms of
the failure of insulin action, and not an epiphenomenon.
The conclusion that IRS-2 plays an important role in medi-
ating the metabolic actions of insulin is supported by several
lines of independent evidence. IRS-2-deficient mice are diabetic
as a result of combined insulin resistance and impaired insulin
production (21), while IRS-1-deficient mice are growth re-
tarded, but mildly insulin-resistant (18, 19). Furthermore, nor-
mal insulin action in liver of IRS-1-deficient mice is associated
with increased phosphorylation of IRS-2 (51). Based on the
2 B.-C. Park and D. Accili, unpublished observation.
FIG. 5. Metabolic responses to insulin in hepatocytes. a, glucokinase activity. Glucokinase activity was measured using a spectrophoto-
metric assay based on generation of NADPH in the absence and presence of insulin. b, glycogen synthesis. Glycogen synthase activity was
measured in insulin-treated WT and 2/2 cells. The effect of insulin was plotted as percentage of the activity measured in the absence of the
allosteric activator glucose 6-phosphate (in both experiments, * 5 p , 0.001). c, insulin suppression of glucose production. Glucose production was
measured in basal and insulin-treated cells over a period of 24 h. Cells were preincubated in the absence of glucose, and glucose released in the
medium was assayed with a glucose analyzer.
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phenotypes of insulin receptor-, IGF-1 receptor-, IRS-1-, and
IRS-2-deficient mice (13–15, 18, 19, 21), one has to conclude
that IRS-1 is predominantly an IGF-1 receptor substrate, and
IRS-2 an insulin receptor substrate. This conclusion is
strengthened by the present findings, indicating that insulin
receptors are required for optimal IRS-2 phosphorylation. By
suggesting that IRS-2 functions primarily as an insulin recep-
tor substrate, our data provide a compelling explanation for the
phenotype of mice lacking IRS-2 (21), and corroborate the find-
ings of Bruning et al. that IRS-1 and IRS-2 are functionally
distinct molecules (22). Substrate selection, however, is likely
to be a more complex event in vivo, as indicated by studies of
mice with combined null mutations of the insulin receptor and
IRS-1 genes, which develop insulin resistant diabetes with
significantly higher frequency than mice heterozygous for each
individual mutation (20).
An important question raised from our studies is why IGF-1
receptors fail to phosphorylate IRS-2 as insulin receptors do.
There is ample evidence that IRS-1 and IRS-2 utilize different
mechanisms to interact with their receptor partners (52–54).
This evidence, however, does not support a different mode of
interaction of insulin and IGF-1 receptors with IRS-1 and
IRS-2. An alternative possibility is that the subcellular local-
ization of IRS-2 in hepatocytes prevents its efficient phospho-
rylation by IGF-1 receptors. A similar mechanism has been
postulated to explain the differences between epidermal
growth factor and insulin signaling (55), but there is no direct
evidence that a similar mechanism may be at play in this
instance.
The failure of insulin at high doses to activate metabolic
responses through IGF-1 receptors is an important finding and
deserves further comment. There has been considerable con-
troversy over the ability of IGF-1 receptors to mediate meta-
bolic actions (56). We have previously shown that IGF-1 recep-
tors are weak mediators of metabolic effects in mice lacking
insulin receptors (17). We postulated that IGF-1 may enhance
peripheral glucose uptake in muscle and decrease hepatic glu-
coneogenesis. Based on those data, we proposed that IGF-1
may act on hepatic glucose production either directly through
IGF-1 receptors, or indirectly through inhibition of glucagon
secretion. The failure of IGF-1 receptors to impinge on hepatic
glucose metabolism favors an indirect mechanism as a more
likely explanation of our previous findings, but further studies
comparing gluconeogenetic rates are required.
The impairment of insulin-mediated growth in 2/2 cells
correlated with the loss of insulin receptor-mediated IRS-2
phosphorylation, suggesting that growth-promoting signaling
of insulin receptors occurs prevalently through IRS-2. On the
other hand, IGF-1-dependent growth occurred normally in 2/2
cells, indicating that IGF-1 receptors signal through IRS-1,
phosphorylation of which is not affected in 2/2 cells. It is
possible that some of the effects of insulin or IGF-1 on growth
are mediated by shc through the grb-2/mSOS pathway to mi-
togen-activated protein kinase (41, 57, 58), although this point
remains controversial (59–61). This possibility is currently
under investigation. However, it is interesting to note that
Bruning and co-workers have shown that IGF-1-dependent
growth of IRS-1-deficient fibroblasts is impaired despite nor-
mal activation of mitogen-activated protein kinase, and cannot
be rescued by IRS-2, consistent with our model in which IGF-1
receptors utilize primarily IRS-1 to mediate their actions on
cell growth (22). The impairment of IGF-2-mediated growth in
2/2 cells is consistent with previous evidence from our labo-
ratory and others that insulin receptors mediate the growth-
promoting actions of IGF-2 (62, 63).
In conclusion, our data support a model in which the speci-
ficity of insulin signaling in liver is bestowed by the formation
of a signaling complex between insulin receptors and IRS-2. It
remains to be seen whether a similar mechanism operates in
other cell types, for example in insulin-dependent translocation
of glucose transporters in skeletal muscle and adipose tissue.
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